Tag: Era

  • KAISER HEALTH NEWS: Era of ‘free’ Covid vaccines, test kits, and treatments is ending. Who will pay the tab now? | News

    KAISER HEALTH NEWS: Era of ‘free’ Covid vaccines, test kits, and treatments is ending. Who will pay the tab now? | News

    Time is running out for totally free-to-shopper covid vaccines, at-home test kits, and even some therapies.

    The White Home introduced this month that the national public wellbeing crisis, to start with declared in early 2020 in response to the pandemic, is established to expire May perhaps 11. When it finishes, so will a lot of of the procedures developed to overcome the virus’s unfold.

    Take vaccines. Right up until now, the federal federal government has been getting covid-19 photographs. It a short while ago bought 105 million doses of the Pfizer-BioNTech bivalent booster for about $30.48 a dose, and 66 million doses of Moderna’s edition for $26.36 a dose. (These are amid the providers that designed the first covid vaccines marketed in the United States.)

    Folks will be in a position to get these vaccines at low or no cost as extensive as the govt-acquired provides last. But even before the conclusion day for the public crisis was set, Congress opted not to provide more money to improve the government’s dwindling stockpile. As a outcome, Pfizer and Moderna had been now preparing their moves into the business industry. Equally have indicated they will raise prices, somewhere in the vary of $110 to $130 per dose, nevertheless insurers and governing administration wellbeing plans could negotiate decreased rates.

    “We see a double-digit billion[-dollar] marketplace chance,” traders have been explained to at a JPMorgan meeting in San Francisco not too long ago by Ryan Richardson, main system officer for BioNTech. The firm expects a gross rate — the total price tag just before any discount rates — of $110 a dose, which, Richardson stated, “is a lot more than justified from a health and fitness economics viewpoint.”

    That could translate to tens of billions of bucks in income for the companies, even if uptake of the vaccines is sluggish. And consumers would foot the invoice, either specifically or indirectly.

    If half of older people — about the same share as people who opt for an annual flu shot — get covid boosters at the new, increased prices, a recent KFF report estimated, insurers, employers, and other payors would shell out $12.4 billion to $14.8 billion. That is up to virtually two times as considerably as what it would have value for every single grownup in the U.S. to get a bivalent booster at the normal selling price compensated by the federal authorities.

    As for covid therapies, an August weblog post by the Office of Health and Human Services’ Administration for Strategic Preparedness and Reaction mentioned that govt-purchased provides of the drug Paxlovid are envisioned to final by midyear ahead of the non-public sector can take around. The government’s bulk order price tag from producer Pfizer was $530 for a program of procedure, and it isn’t nonetheless known what the companies will demand when government provides run out.

    How A lot of That Pinch Will Individuals Come to feel?

    One particular matter is specific: How significantly, if any, of the boosted charges are passed on to individuals will rely on their wellbeing coverage.

    Medicare beneficiaries, those people enrolled in Medicaid — the point out-federal wellness coverage program for folks with small incomes — and men and women with Very affordable Care Act coverage will continue on to get covid vaccines with no charge sharing, even when the general public health unexpected emergency finishes and the govt-bought vaccines run out. A lot of men and women with occupation-based mostly insurance policies will also likely not experience copayments for vaccines, until they go out of community for their vaccinations. People today with constrained-gain or short-time period insurance plan procedures could have to pay out for all or portion of their vaccinations. And persons who really do not have insurance will have to have to both fork out the whole price tag out-of-pocket or seek out no- or minimal-cost vaccinations from community clinics or other suppliers. If they cannot discover a absolutely free or minimal-cost alternative, some uninsured individuals may possibly be forced to skip vaccinations or tests.

    Coming up with what could be $100 or more for vaccination will be primarily hard “if you are uninsured or underinsured which is the place these cost hikes could push further disparities,” said Sean Robbins, government vice president of exterior affairs for the Blue Cross Blue Shield Affiliation. These will increase, he mentioned, will also have an affect on folks with insurance coverage, as the charges “flow via to rates.”

    Meanwhile, general public policy industry experts say lots of non-public insurers will continue on to go over Paxlovid, although people may perhaps deal with a copayment, at minimum until finally they meet up with their deductible, just as they do for other remedies. Medicaid will keep on to deal with it devoid of charge to people until at minimum 2024. But Medicare coverage will be restricted until the remedy goes by way of the standard Food and drug administration process, which usually takes lengthier than the unexpected emergency use authorization it has been promoted less than.

    Another complication: The rolls of the uninsured are very likely to climb more than the upcoming calendar year, as states are poised to reinstate the method of routinely identifying Medicaid eligibility, which was halted for the duration of the pandemic. Starting in April, states will get started reassessing whether Medicaid enrollees meet cash flow and other qualifying factors.

    An estimated 5 million to 14 million people nationwide might reduce coverage.

    “This is our No. 1 concern” appropriate now, said John Baackes, CEO of L.A. Treatment, the nation’s most significant publicly operated wellbeing prepare with 2.7 million users.

    “They could not notice they’ve shed coverage right until they go to fill a prescription” or request other healthcare care, such as vaccinations, he claimed.

    What About Covid Exam Kits?

    Regulations stay in area for insurers, which includes Medicare and Cost-effective Treatment Act plans, to cover the price tag of up to 8 in-property take a look at kits a month for every single individual on the system, till the community wellbeing emergency ends.

    For people — such as individuals with no insurance policy — a governing administration website is still featuring up to four examination kits for every family, till they operate out. The Biden administration shifted funding to invest in additional kits and produced them obtainable in late December.

    Commencing in May possibly, while, beneficiaries in original Medicare and numerous people today with private, task-centered insurance plan will have to start off having to pay out-of-pocket for the quick antigen exam kits. Some Medicare Advantage programs, which are an alternative to authentic Medicare, may well opt to go on covering them without having a copayment. Procedures will change, so test with your insurer. And Medicaid enrollees can carry on to get the take a look at kits devoid of price for a minor about a yr.

    State guidelines also can fluctuate, and continued protection without having expense sharing for covid exams, treatment options, and vaccines immediately after the well being emergency finishes may well be offered with some wellness options.

    In general, the foreseeable future of covid tests, vaccines, and treatment plans will replicate the complicated blend of coverage shoppers currently navigate for most other kinds of care.

    “From a consumer standpoint, vaccines will nevertheless be free, but for solutions and test kits, a large amount of people today will deal with charge sharing,” said Jen Kates, a senior vice president at KFF. “We’re having what was universal obtain and now indicating we’re likely again to how it is in the typical U.S. wellbeing method.”

    KHN correspondent Darius Tahir contributed to this report.

  • Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Hemp, Inc.

    Hemp, Inc.

    Las Vegas, NV, Nov. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWireHemp, Inc. (OTC PINK: HEMP): It’s a new dawn, a new day as the first bill solely related to marijuana is sent to POTUS after being approved by the U.S. House and Senate – an unfathomable feat a decade ago. Passed by unanimous consent, by the Senate, the marijuana-related bill signals times are changing and so are perceptions about marijuana.

    Too many lives have been upended because of our failed approach to marijuana.  It’s time that we right these wrongs. – President Joe Biden
    (Source: White House Briefing Room)

    After years of championing legislation to legalize marijuana for medical purposes, the H.R. 8454 – Medical Marijuana and Cannabidiol (CBD) Research Expansion Act marks a “historic breakthrough in addressing the federal government’s failed and misguided prohibition of cannabis.”

    In a statement released by U.S. Congressman Earl Blumenauer (Founder and Co-chair of the Congressional Cannabis Caucus and Sponsor of the Medical Marijuana and Cannabidiol (CBD)  Research Act), “The public is tired of waiting for the federal government to catch up. Nearly half of our nation’s population now live in states where adult-use of cannabis is legal. For far too long, Congress has stood in the way of science and progress, creating barriers for researchers attempting to study cannabis and its benefits. At a time when more than 155 million Americans reside where adult-use of cannabis is legal at the state or local level and there are four million registered medical marijuana users with many more likely to self-medicate, it is essential that we are able to fully study the impacts of cannabis use.” (Source)

    Per Congress.gov, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will:

    Establish a new, separate registration process to facilitate research on marijuana.

    Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

    The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

    Finally, the bill includes various other provisions, including provisions that:
    ·       require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
    ·       prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
    ·       allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
    ·       require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. (Source: Congress.gov)

    In a nutshell, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will allow a more streamlined approach to the application process for marijuana studies and will remove the barriers that slowed down the process. Research on CBD and other potentially beneficial marijuana-derived substances will be based on sound science without any regulatory hindrance. Yes, there is evidence suggesting marijuana is beneficial in treating glaucoma and epilepsy.  But as Congressmen Andy Harris said, “Only scientific research will prove the veracity of the many claims regarding efficacy for other diseases. Despite lacking much scientific research, over three dozen states have already legalized medical marijuana, and the American public deserves to know the effect modern marijuana has on the human body.”

    When the bill officially reaches President Joe Biden’s desk, he will have 10 days (excluding Sundays) to sign or veto it.  A White House spokesperson confirmed President Biden intends on signing the legislation. Once it’s signed and enacted, the cannabis industry could see a flurry of marijuana-related bills.  MJ Biz Daily reported there are “roughly 50 marijuana-related bills circulating in Congress” with the SAFE Banking Act (a proposed law that will allow state-legal dispensaries to access banking services) expected to have the best chance of passage.  Congressman Blumenauer believes the upcoming enactment of the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act could provide the momentum needed to push it through Congress.

    Why is the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act significant? After numerous failed attempts from past bills, what propelled this one to the President’s desk for signature? It’s the first legislation to unite opponents and proponents of cannabis legalization. Both sides want extensive research done, albeit for different reasons nonetheless. (Source)

    According to an article in Cardinal News, opponents want evidence that marijuana is harmful and proponents want evidence that it’s useful for medical applications. A myriad of questions needs answers. Do we need a surgeon general’s warning? How can marijuana-derived medications treat various health conditions? These are just a couple of questions researchers have not been able to answer because marijuana is a Schedule 1 controlled substance with bureaucratic hurdles and security measures deterring “would-be researchers” from finding the answers.

    This won’t be the case much longer. A new dawn, a new day is here for federal cannabis reform. And as Bruce Perlowin (Hemp, Inc.’s Chief Visionary Consultant) said back in 2015, “you can’t hold back the tide”. Once the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act is signed into law by Biden, the door will be open for new, innovative treatments derived from cannabis that will, hopefully, give patients more treatment options, according to Senate Majority Leader Chuck Schumer.

    Until then, check out Hemp, Inc.’s product lines containing CBD, CBDA, CBG, CBGA, and CBN (non-psychoactive compounds found in cannabis plants). CBD, in particular, is known for pain relief, relaxation, and anxiety relief. Adding CBG to CBD is known to enhance pain relief and CBN is known for helping sleeplessness. When CBN is combined with CBD and CBG, the benefits include relaxation, and reduced anxiety and pain thereby aiding in a better night’s sleep. Hemp, Inc.’s product lines have received rave reviews due to the high potency and effective, real therapeutic dose. The company uses a pharmaceutical-grade beta-cyclodextrin (a carbohydrate used during the manufacturing process) which is combined with CBD and CBG for rapid absorption and uptake. To order these amazing products, click here.

    About Hemp, Inc.
    With more than 10 years of experience in growing and processing hemp in North America, Hemp, Inc. has an established network of industry professionals in every segment of the industrial hemp industry. Hemp, Inc.’s 85,000 square-foot facility on over 9 acres in Spring Hope, N.C. is one of the largest industrial multipurpose hemp processing facilities in North America. Its mission of providing green solutions that help make the world a better place continues to flourish as the company advances an ever-growing portfolio of revenue and value-generating synergistic businesses. Hemp may be the salvation in retooling America for greener, more sustainable domestic manufacturing.

    To catch up with the latest news on Hemp, Inc., be sure to check out:

    Hemp Inc.’s Year to Date Sales Increase 315{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} Over Last Year
    Hemp Inc. Reports Third Quarter Results and Removal of “Yield” Sign
    Hemp Inc. Reveals Stunning Results of its Hemp Research
    Hemp Inc. Applauds President Biden’s Plan to Pardon People Convicted of Simple Marijuana Possession
    Hempcrete Approved for U.S. Residential Construction
    Hemp Inc. See Significant Increase in Revenue Over the Last 3 Quarters
    Global Hemp Fiber Market Rising at an Annual Rate of 6.9{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}
    Hemp, Inc. Offers CBD-CBG Topical Pain Relief Roll-On
    Hemp, Inc.’s Chief Visionary Consultant Bruce Perlowin Brings Opportunity to Hemp, Inc. (August 8, 2022)
    Hemp Inc.’s CBDA and CBGA Products on Sale Now (July 19, 2022)
    Hemp Inc.’s Chief Visionary Consultant Bruce Perlowin talks with Stock Day podcast about Hemp Inc.’s super potent line of CBD/CBG/CBN Products (July 7, 2022)
    Healthy Products for Healthy Living: A Look into Hemp, Inc.’s Pure, Premium, and Potent CBD and Wellness Products (June 16, 2022)
    Hemp, Inc. Releases New High Potency CBD/CBG Vanilla Flavored Coffee Enhancer (June 9, 2022)
    Hemp, Inc.’s King of Hemp CBD-CBG-CBN Natural Sleep Aid Capsules in Stock and On Sale (May 26, 2022)
    King of Hemp Natural and Vanilla-Flavored CBD/CBG “Super” Tinctures Now in Stock (May 12, 2022)

    The Company will continue to keep its shareholders up to date on all pertinent material events, product releases, production plans, and inventory availability. Those interested in distributing on a large-scale basis should email [email protected] or call 877-436-7564 for more information. The entire product line includes tinctures, gummies, capsules, and edibles in a variety of sizes, potencies, flavors, and formulas with a future focus on healthy foods for healthy living.

    Forward-Looking Statements

    This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. The Securities and Exchange Commission (SEC) requires issuers to provide “adequate current information”. Financials for Hemp, Inc. are listed on the OTC Exchange. More information can also be found on the Hemp, Inc. website by visiting www.hempinc.com/hemp-financial-disclosures/. The material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks and uncertainties.

    Contact: Hemp, Inc.
    ir@hempinc.com / (855) 436-7688
    Sales:(877) 436-7564

  • Hemp, Inc. Reports: Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Hemp, Inc. Reports: Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Las Vegas, NV, Nov. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Hemp, Inc. (OTC PINK: HEMP): It’s a new dawn, a new day as the first bill solely related to marijuana is sent to POTUS after being approved by the U.S. House and Senate – an unfathomable feat a decade ago. Passed by unanimous consent, by the Senate, the marijuana-related bill signals times are changing and so are perceptions about marijuana.

    Too many lives have been upended because of our failed approach to marijuana.  It’s time that we right these wrongs. – President Joe Biden
    (Source: White House Briefing Room)

    After years of championing legislation to legalize marijuana for medical purposes, the H.R. 8454 – Medical Marijuana and Cannabidiol (CBD) Research Expansion Act marks a “historic breakthrough in addressing the federal government’s failed and misguided prohibition of cannabis.”

    In a statement released by U.S. Congressman Earl Blumenauer (Founder and Co-chair of the Congressional Cannabis Caucus and Sponsor of the Medical Marijuana and Cannabidiol (CBD)  Research Act), “The public is tired of waiting for the federal government to catch up. Nearly half of our nation’s population now live in states where adult-use of cannabis is legal. For far too long, Congress has stood in the way of science and progress, creating barriers for researchers attempting to study cannabis and its benefits. At a time when more than 155 million Americans reside where adult-use of cannabis is legal at the state or local level and there are four million registered medical marijuana users with many more likely to self-medicate, it is essential that we are able to fully study the impacts of cannabis use.” (Source)

    Per Congress.gov, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will:

    Establish a new, separate registration process to facilitate research on marijuana.

    Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

    The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

    Finally, the bill includes various other provisions, including provisions that:
    ·       require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
    ·       prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
    ·       allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
    ·       require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. (Source: Congress.gov)

    In a nutshell, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will allow a more streamlined approach to the application process for marijuana studies and will remove the barriers that slowed down the process. Research on CBD and other potentially beneficial marijuana-derived substances will be based on sound science without any regulatory hindrance. Yes, there is evidence suggesting marijuana is beneficial in treating glaucoma and epilepsy.  But as Congressmen Andy Harris said, “Only scientific research will prove the veracity of the many claims regarding efficacy for other diseases. Despite lacking much scientific research, over three dozen states have already legalized medical marijuana, and the American public deserves to know the effect modern marijuana has on the human body.” 

    When the bill officially reaches President Joe Biden’s desk, he will have 10 days (excluding Sundays) to sign or veto it.  A White House spokesperson confirmed President Biden intends on signing the legislation. Once it’s signed and enacted, the cannabis industry could see a flurry of marijuana-related bills.  MJ Biz Daily reported there are “roughly 50 marijuana-related bills circulating in Congress” with the SAFE Banking Act (a proposed law that will allow state-legal dispensaries to access banking services) expected to have the best chance of passage.  Congressman Blumenauer believes the upcoming enactment of the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act could provide the momentum needed to push it through Congress.

    Why is the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act significant? After numerous failed attempts from past bills, what propelled this one to the President’s desk for signature? It’s the first legislation to unite opponents and proponents of cannabis legalization. Both sides want extensive research done, albeit for different reasons nonetheless. (Source)

    According to an article in Cardinal News, opponents want evidence that marijuana is harmful and proponents want evidence that it’s useful for medical applications. A myriad of questions needs answers. Do we need a surgeon general’s warning? How can marijuana-derived medications treat various health conditions? These are just a couple of questions researchers have not been able to answer because marijuana is a Schedule 1 controlled substance with bureaucratic hurdles and security measures deterring “would-be researchers” from finding the answers.

    This won’t be the case much longer. A new dawn, a new day is here for federal cannabis reform. And as Bruce Perlowin (Hemp, Inc.’s Chief Visionary Consultant) said back in 2015, “you can’t hold back the tide”. Once the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act is signed into law by Biden, the door will be open for new, innovative treatments derived from cannabis that will, hopefully, give patients more treatment options, according to Senate Majority Leader Chuck Schumer.

    Until then, check out Hemp, Inc.’s product lines containing CBD, CBDA, CBG, CBGA, and CBN (non-psychoactive compounds found in cannabis plants). CBD, in particular, is known for pain relief, relaxation, and anxiety relief. Adding CBG to CBD is known to enhance pain relief and CBN is known for helping sleeplessness. When CBN is combined with CBD and CBG, the benefits include relaxation, and reduced anxiety and pain thereby aiding in a better night’s sleep. Hemp, Inc.’s product lines have received rave reviews due to the high potency and effective, real therapeutic dose. The company uses a pharmaceutical-grade beta-cyclodextrin (a carbohydrate used during the manufacturing process) which is combined with CBD and CBG for rapid absorption and uptake. To order these amazing products, click here.

    About Hemp, Inc.
    With more than 10 years of experience in growing and processing hemp in North America, Hemp, Inc. has an established network of industry professionals in every segment of the industrial hemp industry. Hemp, Inc.’s 85,000 square-foot facility on over 9 acres in Spring Hope, N.C. is one of the largest industrial multipurpose hemp processing facilities in North America. Its mission of providing green solutions that help make the world a better place continues to flourish as the company advances an ever-growing portfolio of revenue and value-generating synergistic businesses. Hemp may be the salvation in retooling America for greener, more sustainable domestic manufacturing.

    To catch up with the latest news on Hemp, Inc., be sure to check out:

    Hemp Inc.’s Year to Date Sales Increase 315{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} Over Last Year
    Hemp Inc. Reports Third Quarter Results and Removal of “Yield” Sign
    Hemp Inc. Reveals Stunning Results of its Hemp Research
    Hemp Inc. Applauds President Biden’s Plan to Pardon People Convicted of Simple Marijuana Possession
    Hempcrete Approved for U.S. Residential Construction
    Hemp Inc. See Significant Increase in Revenue Over the Last 3 Quarters
    Global Hemp Fiber Market Rising at an Annual Rate of 6.9{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}
    Hemp, Inc. Offers CBD-CBG Topical Pain Relief Roll-On
    Hemp, Inc.’s Chief Visionary Consultant Bruce Perlowin Brings Opportunity to Hemp, Inc. (August 8, 2022)
    Hemp Inc.’s CBDA and CBGA Products on Sale Now (July 19, 2022)
    Hemp Inc.’s Chief Visionary Consultant Bruce Perlowin talks with Stock Day podcast about Hemp Inc.’s super potent line of CBD/CBG/CBN Products (July 7, 2022)
    Healthy Products for Healthy Living: A Look into Hemp, Inc.’s Pure, Premium, and Potent CBD and Wellness Products (June 16, 2022)
    Hemp, Inc. Releases New High Potency CBD/CBG Vanilla Flavored Coffee Enhancer (June 9, 2022)
    Hemp, Inc.’s King of Hemp CBD-CBG-CBN Natural Sleep Aid Capsules in Stock and On Sale (May 26, 2022)
    King of Hemp Natural and Vanilla-Flavored CBD/CBG “Super” Tinctures Now in Stock (May 12, 2022)

    The Company will continue to keep its shareholders up to date on all pertinent material events, product releases, production plans, and inventory availability. Those interested in distributing on a large-scale basis should email [email protected] or call 877-436-7564 for more information. The entire product line includes tinctures, gummies, capsules, and edibles in a variety of sizes, potencies, flavors, and formulas with a future focus on healthy foods for healthy living.

    Forward-Looking Statements

    This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. The Securities and Exchange Commission (SEC) requires issuers to provide “adequate current information”. Financials for Hemp, Inc. are listed on the OTC Exchange. More information can also be found on the Hemp, Inc. website by visiting www.hempinc.com/hemp-financial-disclosures/. The material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks and uncertainties.

    Contact: Hemp, Inc.
    [email protected] / (855) 436-7688
    Sales:(877) 436-7564

    Primary Logo

    Source: Hemp, Inc.

    2022 GlobeNewswire, Inc., source Press Releases